VIPIND.NSE News

V.I.P.INDUSTRIES LTD. ( ($IN:VIPIND) ) just unveiled an announcement. V.I.P. Industries has disclosed that the Assistant Commissioner of State Tax,...

In this briefing: Toyota’s $35B Privatization Gamble Hits A Wall—Will A Higher Bid Be Forced? CVS Health: Margin Repair in Motion—What Medicare Advantage and Pharmacy Growth Signal Next! Hybridan Small Cap Feast: 9 February 2026 Endurance Technologies Ltd - Strong Order Wins & Strategic Capex; Margin Upside Largely Priced In VIP Industries Ltd - Near-Term Challenges Continue; Maintain HOLD 1. Toyota’s $35B Privatization Gamble Hits A Wall—Will A Higher Bid Be Forced? The Toyota Motor Corp. group has extended the tender deadline to March 2 for its ¥6.1 trillion ($35 billion) bid to privatize Toyota Industries Corp., underscoring the increasingly delicate math behind the deal. Toyota already owns roughly 25% of Toyota Industries, and investors representing 33% of shares have agreed to tender, leaving the group approximately nine percentage points short of the two-thirds threshold required to push the transaction through. The extension signals that the conglomerate needs additional time to secure support amid vocal opposition from Elliott Investment Management LP, which argues the ¥18,800-per-share offer undervalues the company. 2.

In this briefing: Hybridan Small Cap Feast: 9 February 2026 Endurance Technologies Ltd - Strong Order Wins & Strategic Capex; Margin Upside Largely Priced In VIP Industries Ltd - Near-Term Challenges Continue; Maintain HOLD Minor International Plc. (MINT): Core Profit Beats; Europe Enters 1Q26 Low Season GuocoLand’s Quek Leng Chan Builds Interest 1. Hybridan Small Cap Feast: 9 February 2026 Arecor Therapeutics 80.00p £29.26m (AREC.L) The biopharmaceutical Company focused on drug development and enhanced delivery in diabetes and other cardiometabolic diseases provided a business update for the 12 months ended 31 December 2025. The Company continued focus on two core product areas: diabetes and oral delivery of peptides. A codevelopment deal was signed in September 2025 with Sequel Med Tech to combine Arecor's ultra-concentrated, ultra-rapid-acting (500U/mL) insulin AT278 with Sequel's twist Automated Insulin Delivery (AID) system. 2. Endurance Technologies Ltd - Strong Order Wins & Strategic Capex; Margin Upside Largely Priced In Strong Order book: As of Dec’25, the company has secured total business orders worth ~Rs 5,021 Cr over the last five years, along with cumulative replacement orders of Rs 730 Cr and Rs 4,291 Cr in new orders.

In this briefing: Praj Industries Ltd - Bio-Energy Headwinds Persist; Signs of Growth in Other Businesses Camlin Fine Sciences Ltd. - Blends Steady; Vanillin Poised for Realisation-Driven Growth Endurance Technologies Ltd - Strong Order Wins & Strategic Capex; Margin Upside Largely Priced In Inox Wind Ltd - Q3 Miss on All Fronts Against Consensus VIP Industries Ltd - Near-Term Challenges Continue; Maintain HOLD 1. Praj Industries Ltd - Bio-Energy Headwinds Persist; Signs of Growth in Other Businesses Bio-energy Slowdown Continues: The company’s 1G Ethanol business continues to remain impacted by subdued demand and an extended execution cycle. However, management is witnessing good traction in brownfield projects focused on operational efficiency and value-added product additions. Margin Deteriorating: EBITDA margins declined during the quarter, primarily due to lower export revenue. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Benchmark indices are set for a weak opening, tracking cues from Asian markets.

The company has seen its market share fall to 38% by FY24 as rivals like Safari gained ground.

Keep an eye out for textiles, gems, leather, and shrimp export stocks after Trump imposed an additional 25% tariff on Indian goods. Titan, HPCL, and LIC, among others, are set to report their Q1 earnings later in the day.

The street turned cautious on tech ahead of HCL Tech's results, extending last week’s TCS-triggered selloff.

The analyst said VIP’s underperformance, despite solid volume growth, reflects margin pressure and operational inefficiencies.